Dr Sighild Lemarchant, Axoltis Pharma – PreClinical Project Manager, will participate to Neuroscience 2021, the Annual Meeting of Society for Neuroscience, which will take place online November 8-11, 2021. Dr Lemarchant will present our results about the mechanism of action and the targets engaged by our product NX210, leading to neuroprotection and synaptic transmission improvement. This confirms that our multi-properties product, which is now at clinical stage of development, has a large broad of applications in neurological pathologies.